Poster #L02 by @yatesmark1 et al shows #shielding in #IMID population on biologics may at least in part explain the lower risk of adverse #COVID19 outcomes in this group. Reinforces need for clear guidance on risk mitigation for patients. #ACR20 @RheumNow https://t.co/H4RMbfBrH2